

EVIDÊNCIA CIENTÍFICA

REVISÕES SISTEMÁTICAS

1. Kew BM, Porter RJ, Douglas KM, Glue P, Mentzel CL, Beaglehole B. **Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review.** BJPsych Open. 2023 May 2;9(3):e79. doi: [10.1192/bjo.2023.53](https://doi.org/10.1192/bjo.2023.53).
2. Kelson M, Burnett JM, Matthews A, Juneja T. **Ketamine Treatment for Alcohol Use Disorder: A Systematic Review.** Cureus. 2023 May 3;15(5):e38498. doi: [10.7759/cureus.38498](https://doi.org/10.7759/cureus.38498).
3. Philipp-Muller AE, Stephenson CJ, Moghimi E, Shirazi AH, Milev R, Vazquez G, Reshetukha T, Alavi N. **Combining Ketamine and Psychotherapy for the Treatment of Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.** J Clin Psychiatry. 2023 Feb 6;84(2):22br14564. doi: [10.4088/JCP.22br14564](https://doi.org/10.4088/JCP.22br14564).
4. Jollant F, Colle R, Nguyen TML, Corruble E, Gardier AM, Walter M, Abbar M, Wagner G. **Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review.** Ther Adv Psychopharmacol. 2023 Feb 7;13:20451253231151327. doi: [10.1177/20451253231151327](https://doi.org/10.1177/20451253231151327).
5. Albuquerque TR, Macedo LFR, Delmondes GA, Rolim Neto ML, Almeida TM, Uchida RR, Cordeiro Q, Lisboa KWSC, Menezes IRA. **Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: A systematic review and meta-analysis.** J Cereb Blood Flow Metab. 2022 Dec;42(12):2175-2187. doi: [10.1177/0271678X221116477](https://doi.org/10.1177/0271678X221116477).
6. Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, Di Vincenzo JD, Meshkat S, Ho RCM, Gill H, Teopiz KM, Cao B, Lee Y, McIntyre RS, Rosenblat JD. **Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.** J Psychiatr Res. 2022 Jul;151:693-709. doi: [10.1016/j.jpsychires.2022.04.037](https://doi.org/10.1016/j.jpsychires.2022.04.037).
7. Drozd SJ, Goel A, McGarr MW, Katz J, Ritvo P, Mattina GF, Bhat V, Diep C, Ladha KS. **Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.** J Pain Res. 2022 Jun 15;15:1691-1706. doi: [10.2147/JPR.S360733](https://doi.org/10.2147/JPR.S360733).
8. Ragnhildstveit A, Slayton M, Jackson LK, Brendle M, Ahuja S, Holle W, Moore C, Sollars K, Seli P, Robison R. **Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions.** Brain Sci. 2022 Mar 12;12(3):382. doi: [10.3390/brainsci12030382](https://doi.org/10.3390/brainsci12030382).
9. Schimmers N, Brekxema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA. **Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.** Psychopharmacology (Berl). 2022 Jan;239(1):15-33. doi: [10.1007/s00213-021-06027-y](https://doi.org/10.1007/s00213-021-06027-y). Epub 2021 Nov 23. Erratum in: Psychopharmacology (Berl). 2023 Aug;240(8):1823.
10. Walsh Z, Mollaahmetoglu OM, Rootman J, Golsof S, Keeler J, Marsh B, Nutt DJ, Morgan CJA. **Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.** BJPsych Open. 2021 Dec 23;8(1):e19. doi: [10.1192/bjo.2021.1061](https://doi.org/10.1192/bjo.2021.1061). Erratum in: BJPsych Open. 2022 Jan 18;8(1):e29
11. Conley AA, Norwood AEQ, Hatvany TC, Griffith JD, Barber KE. **Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.** Psychopharmacology (Berl). 2021 Jul;238(7):1737-1752. doi: [10.1007/s00213-021-05825-8](https://doi.org/10.1007/s00213-021-05825-8).
12. Greenway KT, Garel N, Jerome L, Feduccia AA. **Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.** Expert Rev Clin Pharmacol. 2020 Jun;13(6):655-670. doi: [10.1080/17512433.2020](https://doi.org/10.1080/17512433.2020).
13. Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, Cipriani A, Hawton K. **Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.** Aust N Z J Psychiatry. 2020 Jan;54(1):29-45. doi: [10.1177/0004867419888888](https://doi.org/10.1177/0004867419888888).

[10.1177/0004867419883341](https://doi.org/10.1177/0004867419883341). Epub 2019 Nov 15. Erratum in: Aust N Z J Psychiatry. 2020 Jul;54(7):766.

14. Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L. **Ketamine administration in depressive disorders: a systematic review and meta-analysis.** Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. [doi: 10.1007/s00213-014-3664-5](https://doi.org/10.1007/s00213-014-3664-5).
15. Krupitsky EM, Grinenko AY. **Ketamine psychedelic therapy (KPT): a review of the results of ten years of research.** J Psychoactive Drugs. 1997 Apr-Jun;29(2):165-83. [doi: 10.1080/02791072.1997](https://doi.org/10.1080/02791072.1997.10.1080/02791072.1997).

ENSAIOS CLÍNICOS

16. Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B. **Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.** N Engl J Med. 2023 Jun 22;388(25):2315-2325. [doi: 10.1056/NEJMoa2302399](https://doi.org/10.1056/NEJMoa2302399).
17. Kopelman J, Keller TA, Panny B, Griffo A, Degutis M, Spotts C, Cruz N, Bell E, Do-Nguyen K, Wallace ML, Mathew SJ, Howland RH, Price RB. **Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression.** Transl Psychiatry. 2023 May 9;13(1):159. [doi: 10.1038/s41398-023-02451-0](https://doi.org/10.1038/s41398-023-02451-0).
18. Ahmed GK, Elserogy YM, Elfadl GMA, Ghada Abdelsalam K, Ali MA. **Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.** J Affect Disord. 2023 Mar 15;325:127-134. [doi: 10.1016/j.jad.2023.01.005](https://doi.org/10.1016/j.jad.2023.01.005).
19. Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, Hardy L, Warren F, Bloomfield M, Borissova A, Maschauer E, Broomby R, Price R, Coathup R, Gilhooly D, Palmer E, Gordon-Williams R, Hill R, Harris J, Mollaahmetoglu OM, Curran HV, Brandner B, Lingford-Hughes A, Morgan CJA. **Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder.** Am J Psychiatry. 2022 Feb;179(2):152-162. [doi: 10.1176/appi.ajp.2021.21030277](https://doi.org/10.1176/appi.ajp.2021.21030277).
20. Abbar M, Demattei C, El-Hage W, Llorca PM, Samalin L, Demaricourt P, Gaillard R, Courtet P, Vaiva G, Gorwood P, Fabbro P, Jollant F. **Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.** BMJ. 2022 Feb 2;376:e067194. [doi: 10.1136/bmj-2021-067194](https://doi.org/10.1136/bmj-2021-067194).
21. Wilkinson ST, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay B, Fasula M, Elder C, Fenton L, Sanacora G. **Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial.** Psychother Psychosom. 2021;90(5):318-327. [doi: 10.1159/000517074](https://doi.org/10.1159/000517074).
22. Norbury A, Rutter SB, Collins AB, Costi S, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Glasgow AM, Brallier J, Shin LM, Charney DS, Murrough JW, Feder A. **Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence.** Neuropsychopharmacology. 2021 Dec;46(13):2266-2277. [doi: 10.1038/s41386-021-01104-4](https://doi.org/10.1038/s41386-021-01104-4).
23. Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS. **A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.** Am J Psychiatry. 2021 Feb 1;178(2):193-202. [doi: 10.1176/appi.ajp.2020.20050596](https://doi.org/10.1176/appi.ajp.2020.20050596).
24. Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, Nunes EV. **A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.** Am J Psychiatry. 2020 Feb 1;177(2):125-133. [doi: 10.1176/appi.ajp.2019.19070684](https://doi.org/10.1176/appi.ajp.2019.19070684).

25. Basso L, Bönke L, Aust S, Gärtner M, Heuser-Collier I, Otte C, Wingefeld K, Bajbouj M, Grimm S. **Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients.** J Psychiatr Res. 2020 Apr;123:1-8. doi: [10.1016/j.jpsychires.2020.01.002](https://doi.org/10.1016/j.jpsychires.2020.01.002). Corrigendum [J. Psychiatr. Res. 123 (2020) 1-8]. J Psychiatr Res. 2020 May;124:143. doi: [10.1016/j.jpsychires.2020.03.001](https://doi.org/10.1016/j.jpsychires.2020.03.001). Erratum for: J Psychiatr Res. 2020 Apr;123:1-8.
26. Glue P, Neehoff S, Sabadel A, Broughton L, Le Nedelec M, Shadli S, McNaughton N, Medlicott NJ. **Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study.** J Psychopharmacol. 2020 Mar;34(3):267-272. doi: [10.1177/0269881119874457](https://doi.org/10.1177/0269881119874457).
27. Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M, Owoeye O, Batten LA, Blier P. **Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.** Neuropsychopharmacology. 2020 Mar;45(4):606-612. doi: [10.1038/s41386-019-0570-x](https://doi.org/10.1038/s41386-019-0570-x).
28. Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye O, Batten LA, Blier P. **Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.** Am J Psychiatry. 2019 May 1;176(5):401-409. doi: [10.1176/appi.ajp.2018](https://doi.org/10.1176/appi.ajp.2018).
29. Grunebaum MF, Galfalvy HC, Choo TH, Keilp JG, Moitra VK, Parris MS, Marver JE, Burke AK, Milak MS, Sublette ME, Oquendo MA, Mann JJ. **Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.** Am J Psychiatry. 2018 Apr 1;175(4):327-335. doi: [10.1176/appi.ajp.2017.17060647](https://doi.org/10.1176/appi.ajp.2017.17060647).
30. Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubowski E, Bloch MH. **Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.** Neuropsychopharmacology. 2018 Jan;43(2):325-333. doi: [10.1038/npp.2017.194](https://doi.org/10.1038/npp.2017.194).
31. Wilkinson ST, Wright D, Fasula MK, Fenton L, Griep M, Ostroff RB, Sanacora G. **Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.** Psychother Psychosom. 2017;86(3):162-167. doi: [10.1159/000457960](https://doi.org/10.1159/000457960).
32. Liebe T, Li S, Lord A, Colic L, Krause AL, Batra A, Kretschmar MA, Sweeney-Reed CM, Behnisch G, Schott BH, Walter M. **Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial.** Int J Neuropsychopharmacol. 2017 Nov 1;20(11):909-918. doi: [10.1093/ijnp/pyx055](https://doi.org/10.1093/ijnp/pyx055).
33. Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L. **A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.** Am J Psychiatry. 2016 Aug 1;173(8):816-26. doi: [10.1176/appi.ajp.2016.16010037](https://doi.org/10.1176/appi.ajp.2016.16010037).
34. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr. **Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.** Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu039. doi: [10.1093/ijnp/pyu039](https://doi.org/10.1093/ijnp/pyu039). Erratum in: Int J Neuropsychopharmacol. 2016 Apr 27
35. Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D, Charney DS. **Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.** JAMA Psychiatry. 2014 Jun;71(6):681-8. doi: [10.1001/jamapsychiatry.2014.62](https://doi.org/10.1001/jamapsychiatry.2014.62).
36. Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB. **Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.** Neuropsychopharmacology. 2013 Nov;38(12):2475-83. doi: [10.1038/npp.2013.150](https://doi.org/10.1038/npp.2013.150).

37. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. **Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.** Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: [10.1176/appi.ajp.2013.13030392](https://doi.org/10.1176/appi.ajp.2013.13030392).
38. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. **Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence.** J Psychoactive Drugs. 2007 Mar;39(1):13-9. doi: [10.1080/02791072.2007](https://doi.org/10.1080/02791072.2007).
39. Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. **Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.** J Subst Abuse Treat. 2002 Dec;23(4):273-83. doi: [10.1016/s0740-5472\(02\)00275-1](https://doi.org/10.1016/s0740-5472(02)00275-1).

ESTUDOS OBSERVACIONAIS / REAL-WORLD

40. Batiievsky D, Weiner M, Kaplan SB, Thase ME, Maglione DN, Vidot DC. **Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches.** Front Pain Res (Lausanne). 2023 May 19;4:1127863. doi: [10.3389/fpain.2023.1127863](https://doi.org/10.3389/fpain.2023.1127863).
41. Dames S, Kryskow P, Watler C. A Cohort-Based Case Report: **The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression.** Front Psychiatry. 2022 Jan 12;12:803279. doi: [10.3389/fpsyt.2021.803279](https://doi.org/10.3389/fpsyt.2021.803279). Erratum in: Front Psychiatry. 2022 Jul 19;13:962882.
42. Ahuja S, Brendle M, Smart L, Moore C, Thielking P, Robison R. **Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study.** BMC Psychiatry. 2022 Oct 3;22(1):634. doi: [10.1186/s12888-022-04268-5](https://doi.org/10.1186/s12888-022-04268-5).
43. Mollaahmetoglu OM, Keeler J, Ashbullby KJ, Ketzitidou-Argyri E, Grabski M, Morgan CJA. **"This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders.** Front Psychiatry. 2021 Aug 16;12:695335. doi: [10.3389/fpsyt.2021.695335](https://doi.org/10.3389/fpsyt.2021.695335).
44. Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P. **Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.** J Psychoactive Drugs. 2019 Apr-Jun;51(2):189-198. doi: [10.1080/02791072.2019.1587556](https://doi.org/10.1080/02791072.2019.1587556).
45. Hietamies TM, McInnes LA, Klise AJ, Worley MJ, Qian JJ, Williams LM, Heifets BD, Levine SP. **The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis.** J Affect Disord. 2023 Aug 15;335:484-492. doi: [10.1016/j.jad.2023.04.141](https://doi.org/10.1016/j.jad.2023.04.141).
46. Robison R, Brendle M, Moore C, Cross H, Helm L, Darling S, Thayer S, Thielking P, Shannon S. **Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers with COVID-19-Related Burnout and PTSD: A Case Series of Effectiveness/Safety for 10 Participants.** J Psychoactive Drugs. 2023 Mar 2:1-10. doi: [10.1080/02791072.2023.2186285](https://doi.org/10.1080/02791072.2023.2186285).
47. Wolfson PE, Andries J, Ahlers D, Whippo M. **Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses.** Front Psychiatry. 2023 Mar 30;14:1141988. doi: [10.3389/fpsyt.2023.1141988](https://doi.org/10.3389/fpsyt.2023.1141988).
48. Robison R, Lafrance A, Brendle M, Smith M, Moore C, Ahuja S, Richards S, Hawkins N, Strahan E. **A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders.** J Eat Disord. 2022 May 6;10(1):65. doi: [10.1186/s40337-022-00588-9](https://doi.org/10.1186/s40337-022-00588-9).